Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study

Ripretinib provided clinically meaningful activity across mutation subgroups in patients with advanced GIST, demonstrating that ripretinib inhibits a broad range of <i>KIT/PDGFRA</i> mutations in patients with advanced GIST who were previously treated with three or more TKIs.